相关实验视频

Updated: May 30, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

转化治疗不可切除的肝内胆固醇癌使用凝胺加S-1结合PD-1抑制剂:一个病例报告

Shuangying Zhao¹, Xiaodong Zhang¹, Jialiang Luo²

¹Department of Hepatopancreatobiliary Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo, China.

Frontiers in oncology

|January 30, 2025

概括

使用凝胺/S-1和PD-1抑制剂的转化疗法有效地缩小了晚期肝内胆管癌 (iCCA),使手术切除成为可能. 这种免疫化疗方法在患有IIIB期iCCA的患者中实现了完全的病理反应.

科学领域:

肝胆道手术是肝胆道的手术.
医学瘤学医学瘤学
免疫治疗是一种免疫疗法.

背景情况:

肝脏内胆管癌 (iCCA) 是一种高度恶性肝癌.
诊断往往发生在晚期,排除了外科手术的选择.
转化疗法对于晚期iCCA的切除能力至关重要.

研究的目的:

为了评估转化疗法对晚期肝内胆管癌的疗效.
在iCCA中报告结局结合Gemcitabine和S-1 (GS) 与PD-1抑制剂 (Zimberelimab) 的结局.

主要方法:

一名74岁的女性患者患有IIIB期iCCA,接受了6次转化疗程.
治疗包括凝胺加S-1 (GS) 化疗与PD-1抑制剂 (Zimberelimab) 结合.
使用增强型CT扫描来评估瘤反应.

主要成果:

增强CT显示,在6个周期后,瘤大小减少了近一半.
减少了瘤大小,使得成功进行了根性切除.
手术后病理学证实了完全的病理反应.

结论:

吉姆西塔/S-1加PD-1抑制剂治疗是高级iCCA的可行转化策略.
这种方法可以将无法切除的iCCA转换为切除的状态.
成功的转化疗法为高级iCCA患者提供了一种新的治疗途径.

关键词:

在PD-1中使用PD-1.案例报告案例报告转换疗法的转换疗法.免疫疗法联合疗法组合疗法在肝脏内发生的胆固醇癌 (cholangiocarcinoma).

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...